NASDAQ:NLNK NewLink Genetics (NLNK) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free NLNK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.81▼$2.9550-Day Range$0.89▼$14.1052-Week Range$0.82▼$3.60Volume6,500 shsAverage Volume547,540 shsMarket Capitalization$105.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get NewLink Genetics alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About NewLink Genetics Stock (NASDAQ:NLNK)NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details NLNK Stock News HeadlinesMarch 20, 2024 | wsj.comNewlink Technology Inc.March 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earnings reportMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.December 19, 2023 | investing.comNewlink Technology Inc (9600)October 27, 2023 | foxnews.comSuicide and genetics: Study identifies 12 DNA variations that could increase the riskAugust 23, 2023 | forbes.comGenetic Testing Before Pregnancy: What You Need To KnowJune 28, 2023 | thestreet.comWhy NewLink Genetics (NLNK) Stock Is Gaining TodayMay 23, 2023 | fool.comDigimarc (NASDAQ: DMRC)March 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.February 15, 2023 | thestreet.comTrade Ebola Stocks? Sure, But Don't Bet on Big Business OpportunityJanuary 17, 2023 | dailymail.co.ukWill parents take up a DNA test to spot rare diseases? Expert predicts genetic codes of babies could be read by the NHS in as little as five yearsJanuary 14, 2023 | thestreet.comJumpstart ASCO '15 With This Quick List of Hot Research AbstractsJanuary 14, 2023 | thestreet.comCorbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed PositiveAugust 3, 2021 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earningsSee More Headlines Receive NLNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2019Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:NLNK CUSIP65151110 CIK1126234 Webwww.newlinkgenetics.com Phone515-296-5555FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,990,000.00 Net Margins-4,592.84% Pretax MarginN/A Return on Equity-41.50% Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$940,000.00 Price / Sales111.98 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book1.34Miscellaneous Outstanding Shares37,328,000Free FloatN/AMarket Cap$105.26 million OptionableNot Optionable Beta1.17 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Charles J. Link Jr. (Age 60)Co-Founder, Chairman, CEO & Chief Scientific Officer Mr. Nicholas N. Vahanian (Age 52)Co-Founder, Pres, Chief Medical Officer & Director Dr. Eugene P. Kennedy M.D. (Age 50)FACS, Chief Medical Officer Mr. Brian Wiley (Age 51)Chief Commercial Officer Mr. Carl W. Langren (Age 64)CFO & Principal Accounting Officer Key CompetitorsEmergent BioSolutionsNYSE:EBSBolt BiotherapeuticsNASDAQ:BOLTMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLView All Competitors NLNK Stock Analysis - Frequently Asked Questions How were NewLink Genetics' earnings last quarter? NewLink Genetics Corp (NASDAQ:NLNK) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, meeting the consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%. What other stocks do shareholders of NewLink Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Gilead Sciences (GILD). This page (NASDAQ:NLNK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.